Stock Analysis

Teleste Oyj Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

HLSE:TLT1V
Source: Shutterstock

Teleste Oyj (HEL:TLT1V) Full Year 2024 Results

Key Financial Results

  • Revenue: €133.1m (down 12% from FY 2023).
  • Net loss: €5.85m (loss widened by €5.77m from FY 2023).
  • €0.32 loss per share (further deteriorated from €0.004 loss in FY 2023).
earnings-and-revenue-history
HLSE:TLT1V Earnings and Revenue History February 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Teleste Oyj Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates significantly.

The company's shares are up 12% from a week ago.

Risk Analysis

Be aware that Teleste Oyj is showing 4 warning signs in our investment analysis and 2 of those are significant...

Valuation is complex, but we're here to simplify it.

Discover if Teleste Oyj might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About HLSE:TLT1V

Teleste Oyj

Provides broadband, security, and information technologies and related services in Finland and internationally.

Good value slight.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.11% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|23.535% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|1.7389999999999999% overvalued
Jonataninho
Jonataninho
Community Contributor